These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8469900)

  • 21. Current advances in sepsis and septic shock with particular emphasis on the role of insulin.
    Das UN
    Med Sci Monit; 2003 Aug; 9(8):RA181-92. PubMed ID: 12942044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment of sepsis.
    Girbes AR; Beishuizen A; Strack van Schijndel RJ
    Fundam Clin Pharmacol; 2008 Aug; 22(4):355-61. PubMed ID: 18705746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extracorporeal treatments in sepsis: are there new perspectives?
    Tetta C; D'Intini V; Bellomo R; Bonello M; Bordoni V; Ricci Z; Ronco C
    Clin Nephrol; 2003 Nov; 60(5):299-304. PubMed ID: 14640234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-antibiotic strategies for sepsis.
    Cohen J
    Clin Microbiol Infect; 2009 Apr; 15(4):302-7. PubMed ID: 19416301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a.
    Schefold JC; von Haehling S; Corsepius M; Pohle C; Kruschke P; Zuckermann H; Volk HD; Reinke P
    Shock; 2007 Oct; 28(4):418-25. PubMed ID: 17558345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for severe sepsis and septic shock.
    Sharma VK; Dellinger RP
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):395-403. PubMed ID: 16771617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-acetylcysteine in clinical sepsis: a difficult marriage.
    Spapen H
    Crit Care; 2004 Aug; 8(4):229-30. PubMed ID: 15312203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac dysfunction in severe sepsis and septic shock.
    Zanotti-Cavazzoni SL; Hollenberg SM
    Curr Opin Crit Care; 2009 Oct; 15(5):392-7. PubMed ID: 19633546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antithrombin replacement in patients with sepsis and septic shock.
    Giudici D; Baudo F; Palareti G; Ravizza A; Ridolfi L; D' Angelo A
    Haematologica; 1999 May; 84(5):452-60. PubMed ID: 10329925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis and innovative treatment of septic shock.
    Ognibene FP
    Adv Intern Med; 1997; 42():313-38. PubMed ID: 9048123
    [No Abstract]   [Full Text] [Related]  

  • 31. A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock.
    Wheatley C
    Med Hypotheses; 2006; 67(1):124-42. PubMed ID: 16545917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity.
    Kojika M; Sato N; Yaegashi Y; Suzuki Y; Suzuki K; Nakae H; Endo S
    Ther Apher Dial; 2006 Feb; 10(1):12-8. PubMed ID: 16556131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome.
    Manley MO; O'Riordan MA; Levine AD; Latifi SQ
    Shock; 2005 Jun; 23(6):521-6. PubMed ID: 15897804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Plasmapheresis in the treatment of septic shock].
    Busund R
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):776-8. PubMed ID: 15039806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of endotoxin in human septic shock: therapeutic potential of lipid A analogs.
    Danner RL; Parrillo JE
    Prog Clin Biol Res; 1989; 286():183-200. PubMed ID: 2648410
    [No Abstract]   [Full Text] [Related]  

  • 36. Issues in the adjunct therapy of severe sepsis.
    Verhoef J; Hustinx WM; Frasa H; Hoepelman AI
    J Antimicrob Chemother; 1996 Aug; 38(2):167-82. PubMed ID: 8877531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent clinical trials for sepsis: analysis of the results and future perspectives].
    Wakabayashi G; Shimazu M; Tanabe M; Ueda M; Hoshino K; Morikawa Y; Kitajima M
    Nihon Geka Gakkai Zasshi; 1999 Oct; 100(10):674-8. PubMed ID: 10570778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do monoclonal antibodies and anticytokines still have a future in infectious diseases?
    Cohen J; Heumann D; Glauser MP
    Am J Med; 1995 Dec; 99(6A):45S-52S; discussion 52S-53S. PubMed ID: 8585536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of therapeutic agents: morphologic changes and survival data in dogs subjected to endotoxin during the shock tour.
    Brunson JG; Schulz DM; Angevine DM; Imrie ST; Douglas BH
    J Okla State Med Assoc; 1966 Aug; 59(8):477-84. PubMed ID: 5944537
    [No Abstract]   [Full Text] [Related]  

  • 40. Adjunctive therapy for septic shock: a review of experimental approaches.
    Lynn WA; Cohen J
    Clin Infect Dis; 1995 Jan; 20(1):143-58. PubMed ID: 7727640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.